GH Research PLC
GHRS16.690USD
-2.810-14.41%
Handelsschluss 07/22, 16:00（ET）Kurse um 15 Minuten verzögert
1.04BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über GH Research PLC Unternehmen
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Unternehmensinformationen
BörsenkürzelGHRS
Name des UnternehmensGH Research PLC
IPO-datumJun 25, 2021
Gegründet am2021
CEODr. Velichka (Villy) Valcheva, M.D.
Anzahl der mitarbeiter50
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
AddresseJoshua Dawson House
StadtDUBLIN
BörseNASDAQ Global Market Consolidated
LandIreland
PostleitzahlD02 RY95
Telefon35314378334
Website
BörsenkürzelGHRS
IPO-datumJun 25, 2021
Gegründet am2021
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Velichka (Villy) Valcheva, M.D.
Dr. Velichka (Villy) Valcheva, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
RA Capital Management, LP
11.20%
Lynx1 Capital Advisors LLC
10.39%
Terwey (Theis)
9.98%
Other
30.31%
Aktionäre
Aktionäre
Anteil
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
RA Capital Management, LP
11.20%
Lynx1 Capital Advisors LLC
10.39%
Terwey (Theis)
9.98%
Other
30.31%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
33.88%
Hedge Fund
24.16%
Investment Advisor
18.53%
Venture Capital
12.14%
Investment Advisor/Hedge Fund
9.67%
Research Firm
4.41%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
81
63.75M
102.78%
+7.18M
2025Q1
80
63.74M
102.77%
+7.17M
2024Q4
74
51.85M
85.10%
-3.62M
2024Q3
76
51.78M
99.44%
-4.46M
2024Q2
78
51.68M
99.26%
-4.52M
2024Q1
77
50.90M
97.75%
-4.57M
2023Q4
73
50.91M
97.80%
-2.89M
2023Q3
74
50.54M
97.15%
-4.64M
2023Q2
82
51.15M
98.33%
-4.53M
2023Q1
76
51.21M
98.45%
-5.44M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Schonharting (Florian)
14.82M
23.9%
--
--
Dec 31, 2024
BVF Partners L.P.
8.83M
14.23%
-1.57M
-15.12%
Mar 31, 2025
RA Capital Management, LP
6.94M
11.2%
+257.96K
+3.86%
Mar 31, 2025
Lynx1 Capital Advisors LLC
6.44M
10.39%
+90.87K
+1.43%
Mar 31, 2025
Terwey (Theis)
6.19M
9.98%
--
--
Dec 31, 2024
RTW Investments L.P.
5.50M
8.87%
+2.17M
+65.30%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.25M
6.85%
+1.76M
+70.85%
Mar 31, 2025
Cormorant Asset Management, LP
2.01M
3.24%
+1.42M
+238.84%
Mar 31, 2025
Deep Track Capital LP
2.00M
3.22%
+2.00M
--
Mar 31, 2025
TD Securities, Inc.
1.97M
3.17%
+1.97M
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
AdvisorShares Psychedelics ETF
4.37%
iShares MSCI Ireland ETF
0.9%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
SPDR S&P International Small Cap ETF
0.02%
ALPS Medical Breakthroughs ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
AdvisorShares Psychedelics ETF
Anteil4.37%
iShares MSCI Ireland ETF
Anteil0.9%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.89%
SPDR S&P International Small Cap ETF
Anteil0.02%
ALPS Medical Breakthroughs ETF
Anteil0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
